In a phase III trial, the MONALEESA-3 trial, postmenopausal women with advanced HR-positive/HER2-negative breast cancer were randomized to receive ribociclib plus fulvestrant or placebo plus fulvestrant: the median progression-free survival was 20.5 months in the ribociclib arm, as compared to 12.8 months in the placebo arm [358]. Here, ERBB2 is linked to breast carcinoma.